Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.64 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.64 |
| ▸ | PPARA | Q07869 | 4/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 4/20 | 0.46 |
| ▸ | CTSS | P25774 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8910228 | 1.00 | MTNR1A (0.64) | MTNR1AMTNR1BPPARAPPARGPPARD | |
| SCHEMBL5142486 | 0.84 | PPARA (0.64) | MTNR1AMTNR1BPPARAPPARGPPARD | |
| SCHEMBL4671738 | 0.84 | PPARA (0.64) | MTNR1AMTNR1BPPARAPPARGPPARD | |
| SCHEMBL4671732 | 0.84 | PPARA (0.64) | MTNR1AMTNR1BPPARAPPARGPPARD | |
| SCHEMBL15866036 | 0.84 | PPARA (0.48) | MTNR1AMTNR1BPPARAPPARGPPARD | |
| SCHEMBL2945955 | 0.83 | ATM (0.50) | MTNR1AMTNR1BPPARAPPARGPPARD | |
| SCHEMBL22202986 | 0.83 | ATM (0.47) | MTNR1AMTNR1BPPARAPPARGPPARD | |
| SCHEMBL22202893 | 0.82 | CTSK (0.50) | MTNR1AMTNR1BPPARAPPARGPPARD | |
| SCHEMBL22409417 | 0.82 | PLA2G10 (0.50) | MTNR1AMTNR1BPPARAPPARGPPARD | |
| SCHEMBL2951876 | 0.82 | NFKB1 (0.53) | MTNR1AMTNR1BPPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370807-B2 | Process for preparing sulfonamide compounds | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-06-28 | — | — | US | disclosed |
| US-20220009952-A1 | PROCESS FOR PREPARING SULFONAMIDE COMPOUNDS | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2022-01-13 | — | — | US | disclosed |
| WO-2020140956-A1 | PROCESS FOR PREPARING SULFONAMIDE COMPOUNDS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-07-09 | — | — | WO | disclosed |
| EP-0603348-A1 | PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-06-29 | — | — | EP | disclosed |
| WO-1993023418-A1 | PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370807-B2 | Process for preparing sulfonamide compounds | BCL2, BCL3, BAX | MTNR1A 4339/4885MTNR1B 4365/4885PPARA 1730/4885 |
| US-20220009952-A1 | PROCESS FOR PREPARING SULFONAMIDE COMPOUNDS | BCL2, BCL3, BAX | MTNR1A 4339/4885MTNR1B 4365/4885PPARA 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.